Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Current Assets (2020 - 2025)

Gain Therapeutics has reported Current Assets over the past 6 years, most recently at $10.5 million for Q3 2025.

  • Quarterly results put Current Assets at $10.5 million for Q3 2025, down 23.46% from a year ago — trailing twelve months through Sep 2025 was $10.5 million (down 23.46% YoY), and the annual figure for FY2024 was $11.6 million, down 34.74%.
  • Current Assets for Q3 2025 was $10.5 million at Gain Therapeutics, up from $9.3 million in the prior quarter.
  • Over the last five years, Current Assets for GANX hit a ceiling of $47.4 million in Q1 2021 and a floor of $9.3 million in Q2 2025.
  • Median Current Assets over the past 5 years was $18.5 million (2024), compared with a mean of $22.9 million.
  • Biggest five-year swings in Current Assets: surged 319.7% in 2021 and later tumbled 49.8% in 2025.
  • Gain Therapeutics' Current Assets stood at $37.7 million in 2021, then plummeted by 44.09% to $21.1 million in 2022, then decreased by 15.71% to $17.8 million in 2023, then plummeted by 34.74% to $11.6 million in 2024, then dropped by 9.35% to $10.5 million in 2025.
  • The last three reported values for Current Assets were $10.5 million (Q3 2025), $9.3 million (Q2 2025), and $11.2 million (Q1 2025) per Business Quant data.